Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
27 févr. 2024 08h30 HE
|
Imunon, Inc.
Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations
19 oct. 2023 08h30 HE
|
Imunon, Inc.
“A Tale of Two Pandemics: Lessons From the 1889 & 2019 Pandemics” presented by the Foreign Policy Association LAWRENCEVILLE, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
18 oct. 2023 08h30 HE
|
Imunon, Inc.
The MRD trial will evaluate the effect of this treatment combination on minimal residual disease. LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus
24 août 2023 16h05 HE
|
Imunon, Inc.
CRADA will evaluate the immunogenicity and efficacy of two DNA-based Lassa virus vaccine candidates in animal models LAWRENCEVILLE, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
IMUNON Unveils New Manufacturing Capabilities at Huntsville’s HudsonAlpha Biotech Campus
27 juin 2023 12h00 HE
|
Imunon, Inc.
Production of cGMP Clinical Materials Supports R&D Efficiencies and Lowers Costs for Infectious Disease and Cancer Vaccines, and Non-viral DNA-based Immuno-Oncology Therapies HUNTSVILLE, Ala.,...
IMUNON Enters into Collaborative Research Agreement with The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform
05 janv. 2023 08h30 HE
|
Imunon, Inc.
LAWRENCEVILLE, NJ and PHILADELPHIA, PA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, and The Wistar Institute, a global leader in...
IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 – December 1, 2022
22 nov. 2022 08h30 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief Executive...
Celsion Corporation Announces Company Name Change to Imunon, Inc.
19 sept. 2022 16h30 HE
|
Celsion Corporation
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion...
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07 sept. 2022 09h15 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief...
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
19 juil. 2022 08h30 HE
|
Celsion Corporation
Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on...